Comparison of effectiveness and Optimal dosing of Torasemide and Furosemide in the patients of Cirrhosis with ascites in Indian population.

Comparison of efficacy and Optimal dosing of Torasemide and Furosemide in the patients of Cirrhosis with ascites in Indian population.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023602

Enrollment

110

Registered

2020-02-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Torasemide & Furosemide(Loop Diuretics) in patients of cirrhosis with ascites: Comparing efficacy and dosing of torasemide 20mg PO and furosemide 40mg PO in patients of cirrhosis with a

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age >18 ,consenting to participate in study 2.All consecutive hospitalized patients of cirrhosis with ascites irrespective of etiology. 3.Diagnosis of the patients will be made on the basis of LFTs, radiological investigations, upper GI endoscopy, ascitic fluid analysis and liver biopsy if needed, 4.Grade 2 &3 ascites

Exclusion criteria

Exclusion criteria: 1.Refusal to participate 2.Overt Hepatic Encephalopathy, Active Upper GI Bleed, Acute Kidney Injury, Chronic Kidney Disease Stage-4, Spontaneous Bacterial Peritonitis , Hepatocellular Carcinoma , Hepatic venous outflow obstruction, ,HIV,Non Cirrhotic Portal Hypertension, Portal venous thrombosis. 3. Ascites due to other causes like tuberculosis, constrictive pericarditis, etc. 4.Pregnancy

Design outcomes

Primary

Measure	Time frame
Reduction in body weight, increase in urine output, NatriuresisTimepoint: 3,6,9 days	—

Secondary

Measure	Time frame
decrease in abdominal girth, increase in Plasma Renin, increase plasma aldosterone. hepatic encephalopathy, hyponatremia , hypokalemia, hyperkalemia Timepoint: 3,6,9,days	—

Countries

India

Contacts

Public ContactDr Anirudh Tiwari

Kalinga Institute of Medical sciences

dibyalochanpraharaj@gmail.com7087517755

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026